NeoGenomics beats second quarter 2026 estimates on 11% revenue growth and raises full-year guidance.

NeoGenomics reported second quarter revenue of $202 million, an 11% year-over-year increase, and GAAP EPS of $0.02, compared to a loss of $0.35 in the prior year. The results beat consensus estimates for both revenue and EPS, prompting the company to raise its full-year 2026 guidance for revenue and adjusted EBITDA.

Key Highlights

• Clinical services revenue grew 14% to $187 million, driven by a 26% increase in Next-Generation Sequencing (NGS) revenue.
• The average revenue per clinical test increased by 12% to $515, reflecting a continued mix shift to more advanced testing modalities.
• Adjusted EBITDA increased 36% year-over-year to $14 million.
• Full-year 2026 revenue guidance was raised to a new range of $802 million to $806 million, up from $797 million to $803 million previously.